Upcoming Events
This page is focused on publicly-accessible events related to the CTN and/or hosted by NIDA, Nodes, CTN study teams, or CTN SIGs and committees. We also list some major national/international conferences of particular interest to the Network.
For more national/international conferences and events, visit NIDA’s Meetings & Events page and this list from the journal Addiction.
Events
Calendar of Events
|
Monday
|
Tuesday
|
Wednesday
|
Thursday
|
Friday
|
Saturday
|
Sunday
|
|---|---|---|---|---|---|---|
1 event,
-
The Primary Care SIG aims to engage primary care in research, develop substance use treatment interventions relevant to community-based practice, and promote the transfer of evidence-based results from substance use research into community-based practices.  In their next online meeting, Steven Shoptaw, PhD (UCLA) will present on "Whole-Person Primary Care for People Who Use Methamphetamine: Hearts, Lungs, Bugs, and Brains." Join Zoom Meeting Meeting ID: 943 3434 2090 Passcode: 370819 |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
1 event,
-
Join the CTN Western States Node and the Northwest and Pacific Southwest Addiction Technology Transfer Centers (ATTCs) for their next joint webinar! In this session, Erin Winstanley, PhD (CTN Appalachian Node), will describe a NIDA Clinical Trials Network study, CTN-0135, examining clinician-reported challenges with initiating buprenorphine for people using fentanyl, including precipitated or prolonged withdrawal, patient reports that buprenorphine was ineffective, and patient preference for methadone. In response to these challenges, most clinicians surveyed reported modifying their standard induction protocols or patient counseling approaches. Clinicians treating larger patient volumes, seeing a high proportion of patients using fentanyl, or initiating treatment in non-inpatient settings were more likely to report difficulties starting patients on buprenorphine. Dr. Winstanley will present the study results and discuss their implications. 1.5 CME/CE credits available! For information about credit types and accreditation, as well as learning objectives for this session, download the webinar flyer. |
1 event,
-
This session will review changes in the opioid overdose crisis and innovations in opioid use disorder treatment, including novel approaches to initiating buprenorphine, use of long-acting injectable buprenorphine, and strategies for methadone initiation in general medical settings. |
0 events,
|
0 events,
|
0 events,
|